Clinical Trial Update: Ruxolitinib for Premalignant Breast Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ruxolitinib for premalignant breast diseases (Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Ductal Hyperplasia
• Atypical Lobular Hyperplasia
• Ductal Carcinoma in Situ
• Lobular Carcinoma in Situ

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Julie Nangia | Conditions: Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia | Phase 2 | Status: COMPLETED